IceCure Medical has issued bonds worth US$5.7 million
IceCure Medical Ltd. has completed a fundraising to refinance and develop the company.
IceCure is an Israeli medical device company that has developed technology to eliminate benign and cancerous tumors in the breast and other parts of the body by freezing the tumor during treatment in a clinic and without surgery, using the ProSense system developed at the Elisha Private Hospital in Haifa.
Oaklins’ team in Israel advised IceCure Medical Ltd. and acted as the leader of the distributors’ consortium.
Talk to the deal team
Related deals
CARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
Learn morePrestige Inhome Care has found a long-term strategic partner
Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Learn moreCara Care has been acquired by Mahana Therapeutics
Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.
Learn more